Our laboratory focuses on studying how distinct metabolic properties of AML and MDS stem cells can lead to targets for these diseases. In AML, we and others have demonstrated that the JAK/STAT3 pathway is hyper-activated in leukemia stem cells. We focus on the role STAT3 in the mitochondria as a potential target for this disease. In MDS, we focus on how splicing mutations alter the metabolic properties of MDS stem cells.
